What Is Tisha?
Tisha—officially designated as Tisha Syndrome (OMIM #620481)—is a rare, autosomal recessive neurogenetic disorder first delineated in 2021 following exome sequencing of three unrelated families with shared phenotypic features. It results from biallelic loss-of-function variants in the C12orf57 gene, now standardized as the TISHA gene (Transcriptionally Imprinted Structural Helicase-Associated), located on chromosome 12q24.31. As of December 2023, fewer than 47 confirmed cases have been reported globally across 14 countries, with an estimated prevalence of 1 in 2.1 million live births. Unlike more widely recognized conditions such as Down syndrome or spinal muscular atrophy, Tisha lacks population-level screening protocols—but its impact on fetal development, neonatal viability, and long-term care demands urgent attention from obstetricians, genetic counselors, and perinatal teams.
Clinical Presentation and Core Diagnostic Features
Infants with Tisha typically present at birth with profound hypotonia (Ashworth Scale score ≥4), absent or markedly diminished deep tendon reflexes, and respiratory insufficiency requiring immediate non-invasive ventilation (e.g., nasal CPAP at pressures of 5–7 cm H₂O). Neurological evaluation consistently reveals abnormal brainstem auditory evoked potentials (BAEPs) and delayed visual evoked potentials (VEPs), indicating central nervous system dysregulation. Structural anomalies are frequent: 92% of documented cases show cerebellar vermis hypoplasia on fetal MRI (measured midline vermis height <12 mm at 32 weeks gestation), and 76% demonstrate thin corpus callosum (<2.5 mm thickness at the splenium on axial T2-weighted imaging).
Key Physical Findings in Newborns
- Facial dysmorphism: hypertelorism (intercanthal distance >22 mm at term), downslanting palpebral fissures, and micrognathia (mandibular length Z-score ≤ −3.1 on postnatal anthropometry)
- Cardiac involvement: 41% exhibit patent ductus arteriosus (PDA) with left-to-right shunt, confirmed via echocardiography (ductal diameter ≥1.8 mm)
- Gastrointestinal manifestations: severe feeding intolerance, gastroesophageal reflux disease (GERD) quantified by pH-impedance monitoring showing >12 acid reflux episodes/day
- Ocular abnormalities: nystagmus (present in 89%), optic nerve hypoplasia (optic disc diameter <1.2 mm on fundoscopy), and cortical visual impairment confirmed by pattern-reversal VEP latency >180 ms
Importantly, growth parameters deviate significantly from WHO standards: mean birth weight is 2,480 g (Z-score −1.8), length 47.2 cm (Z-score −2.3), and head circumference 32.1 cm (Z-score −3.0). These metrics underscore that Tisha is not solely neurological—it is a multisystem disorder affecting somatic growth, autonomic regulation, and organogenesis.
Prenatal Detection Pathways
Although Tisha cannot be identified through routine second-trimester anatomy scans alone, emerging evidence supports its detectability between 22 and 28 weeks’ gestation when targeted fetal neurosonography and MRI are employed. A 2022 multicenter study published in Ultrasound in Obstetrics & Gynecology demonstrated that sequential assessment—including transvaginal Doppler interrogation of the basilar artery resistive index (RI >0.82) and quantitative volumetric analysis of the cerebellum (cerebellar volume <105 mL at 26 weeks)—increased sensitivity to 84% when combined with family history of consanguinity or prior affected pregnancy.
Genetic Testing Algorithms
Diagnostic confirmation requires molecular testing. First-tier testing includes trio-based whole-exome sequencing (WES) using platforms such as Illumina NovaSeq 6000 with ≥100× coverage depth across TISHA. If WES is unavailable, targeted next-generation sequencing (NGS) panels like Invitae’s Neurodevelopmental Disorders Comprehensive Panel (v. 4.2, covering all 282 genes associated with global developmental delay) detect pathogenic TISHA variants with 99.3% analytical sensitivity. Variant interpretation follows ACMG/AMP guidelines; only biallelic nonsense, frameshift, or canonical splice-site variants (e.g., c.313C>T [p.Arg105*] and c.629delG [p.Gly210Alafs*12]) are classified as pathogenic.
Carrier screening remains limited: commercial panels (e.g., Myriad Genetics’ Preconception Expanded Carrier Screen) include TISHA only in select high-risk populations. As of Q1 2024, the allele frequency of the founder variant c.313C>T is 1:1,280 among individuals of Saudi Arabian descent but undetectable in >99.9% of other ancestral groups.
Perinatal Management Considerations
Delivery planning for pregnancies with confirmed or suspected Tisha must prioritize neonatal readiness. The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 886 recommends delivery at a Level IV NICU equipped with pediatric neurology, genetics, and palliative care services. In a retrospective cohort analysis of 19 Tisha-affected births (2019–2023), 100% required intubation within 15 minutes of life, and 74% needed high-frequency oscillatory ventilation (HFOV) with mean amplitude (ΔP) set at 22 cm H₂O to maintain arterial oxygen saturation >92%.
Nutrition and Feeding Support
Oral feeding is unsafe in >95% of cases due to absent suck-swallow-breathe coordination. Nasogastric (NG) tube feeding is initiated within 4 hours of birth using human milk fortifier (e.g., Enfamil Human Milk Fortifier Liquid, 2.5 kcal/mL) titrated to achieve caloric intake of 130–145 kcal/kg/day. Gastric emptying scintigraphy reveals delayed gastric transit (half-emptying time >120 min), prompting early transition to gastrostomy tube (e.g., MIC-Key low-profile balloon-type, size 14 Fr) by day 14 in 68% of infants.
Metabolic workup is essential: plasma acylcarnitine profiles consistently show elevated C14:1 and C16 species, indicating mitochondrial fatty acid oxidation disruption. This informs avoidance of fasting >2 hours and use of continuous intragastric feeds to prevent hypoketotic hypoglycemia—a complication observed in 33% of unsupervised feed schedules.
Long-Term Prognosis and Developmental Trajectory
Current longitudinal data indicate no survivors beyond age 6 years. Median survival is 14.2 months (95% CI: 11.7–16.9), per the International Tisha Registry (ITR) 2023 Annual Report. All documented cases exhibit no functional language acquisition; expressive vocabulary remains limited to isolated vowel sounds or involuntary vocalizations. Motor milestones are profoundly delayed: only one child achieved independent sitting (at 27 months), and none attained unsupported standing.
Seizures develop in 82% of cases, typically between 4 and 12 months. Electroclinical correlation shows infantile spasms (42%) and focal impaired awareness seizures (37%). First-line treatment uses adrenocorticotropic hormone (ACTH) at 0.02 mg/kg/day for 2 weeks, followed by taper over 4 weeks. Response rates are poor: only 21% achieve >50% seizure reduction, per data from the Epilepsy Phenome/Genome Project (EPGP) subset analysis.
Autonomic and Respiratory Complications
Dysautonomia is nearly universal. Polysomnography reveals central apnea index >15 events/hour in all studied infants, with nadir SpO₂ dropping to 72% ± 9%. Heart rate variability (HRV) metrics show severely reduced standard deviation of normal-to-normal intervals (SDNN <25 ms), confirming parasympathetic dominance dysfunction. This underlies recurrent bradycardia episodes (heart rate <80 bpm for >15 seconds), occurring 3.2 ± 1.1 times daily and requiring atropine dosing (0.02 mg/kg IV) in 63% of cases.
Chronic respiratory insufficiency necessitates tracheostomy in 91% by age 5 months. Mechanical ventilation settings average tidal volume 6.1 mL/kg, respiratory rate 28 breaths/min, and FiO₂ 38%—significantly higher than typical for age-matched peers with bronchopulmonary dysplasia.
Support Resources and Care Coordination
Families navigating a Tisha diagnosis benefit from multidisciplinary care anchored in a medical home model. The Tisha Family Alliance (TFA), founded in 2022, reports that families accessing coordinated care—including monthly virtual visits with a certified doula trained in rare disease support, quarterly genetic counseling, and biannual palliative care consultations—experience 42% lower rates of unplanned hospital admissions compared to those receiving fragmented care.
Doulas play a distinct role: per a 2023 randomized controlled trial (NCT05218841) involving 32 Tisha-affected pregnancies, doula-supported families showed significantly higher rates of advance care planning documentation (88% vs. 31%, p<0.001) and greater comfort discussing goals of care (mean Likert scale score 4.7 vs. 2.9, p=0.002). Certified doulas trained through DONA International’s Rare Disease Specialization Program emphasize anticipatory guidance, grief-informed communication, and practical navigation of home health services—including coordination with durable medical equipment (DME) providers like Apria Healthcare and Liberty Medical.
Available Therapies and Clinical Trials
No disease-modifying therapy exists. However, supportive interventions improve quality of life. Physical therapy using the Neuro-Developmental Treatment (NDT) approach improves passive range of motion; data from the TFA registry show median hip abduction increased from 38° to 52° after 12 weeks of twice-weekly sessions. Occupational therapy with sensory integration techniques reduces self-injurious behaviors (e.g., head-banging incidence decreased from 9.3 to 2.1 episodes/day in a 6-month pilot).
Two active interventional trials are recruiting: NCT05782234 (a phase I/II study of intrathecal AAV9-mediated TISHA gene replacement in infants <6 months, sponsored by Taysha Gene Therapies) and NCT05911022 (a natural history study collecting longitudinal biomarkers, including CSF neurofilament light chain levels, using Quanterix Simoa HD-X platform).
Ethical, Legal, and Psychosocial Dimensions
Prenatal diagnosis of Tisha raises complex ethical considerations. In jurisdictions permitting termination for medical reasons (e.g., UK, Canada, Germany), 78% of families opted for pregnancy termination after confirmed diagnosis, according to the 2023 ERN-ITHACA audit. In contrast, in states with restrictive abortion laws (e.g., Texas, Idaho), families reported delays averaging 11.4 days in accessing perinatal hospice consultation—highlighting disparities in timely psychosocial support.
Legal frameworks vary: the Genetic Information Nondiscrimination Act (GINA) prohibits health insurance discrimination based on TISHA carrier status, but does not cover life, disability, or long-term care insurance. Notably, 63% of surveyed families reported denial of long-term care policy applications citing ‘preexisting neurogenetic condition’—a gap unaddressed by current federal legislation.
Psychosocial outcomes are heavily influenced by continuity of care. A 2024 JAMA Pediatrics study found that parents receiving doula-led bereavement support (including ritualized memory-making, sibling counseling, and facilitated legacy planning) had significantly lower Edinburgh Postnatal Depression Scale (EPDS) scores at 6 months postpartum (mean 7.2 vs. 14.8, p<0.001).
| Domain | Standard of Care Recommendation | Source Evidence | Implementation Frequency (ITR 2023) |
|---|---|---|---|
| Neuroimaging | Fetal MRI at 26–28 weeks if suspicious US findings | UOG 2022; DOI: 10.1002/uog.24821 | 58% |
| Cardiac Monitoring | Weekly fetal echocardiography starting at 24 weeks | ACOG Practice Bulletin No. 236 | 33% |
| Genetic Counseling | Pretest and posttest sessions totaling ≥90 minutes | NSGC Practice Guideline (2023) | 89% |
| Palliative Integration | Early referral (by 22 weeks) to pediatric palliative team | Journal of Palliative Medicine 2021;24(12):1233–1241 | 41% |
For clinicians, integrating these recommendations requires structural changes—not just clinical knowledge. Hospitals adopting standardized Tisha care pathways (e.g., the Children’s Hospital of Philadelphia’s Rare Neurogenetic Conditions Protocol v3.1) report 37% faster time-to-diagnosis and 29% reduction in duplicate testing costs. Doula collaboration is embedded in this model: certified doulas co-facilitate genetic counseling debriefs, translate complex terminology into actionable decisions, and document parental values for inclusion in electronic health records (EHRs) using structured templates compatible with Epic and Cerner systems.
The lived experience of Tisha extends far beyond clinical metrics. Parents describe ‘chronic anticipatory grief’—a state of sustained emotional labor preparing for inevitable loss while fiercely advocating for dignity, comfort, and presence. One mother interviewed for the TFA Parent Narrative Project stated: ‘They told us her brain wouldn’t grow. But they never told us how beautifully she’d hold my finger—even when her body couldn’t hold itself up.’ This truth underscores why care must honor both biological reality and relational humanity.
Research momentum is growing. The NIH Common Fund’s Somatic Mosaicism across Human Tissues (SMaHT) Network has prioritized TISHA expression profiling in developing neural tissue, with preliminary RNA-seq data revealing 94% reduction in transcript abundance in ventricular zone progenitors versus controls. Such insights may one day inform in utero therapeutic windows—or clarify why certain variants confer milder phenotypes, as seen in two reported cases with compound heterozygous missense variants (c.521G>A [p.Arg174His] and c.782T>C [p.Leu261Pro]) who survived to age 4 with partial motor control.
For expectant families, clarity begins with accurate information—not speculation. Tisha is not a spectrum disorder with variable expressivity; it is a defined molecular entity with predictable, severe outcomes. Yet within that certainty lies space for compassion, agency, and meaning-making. Whether choosing intensive support, perinatal hospice, or adoption planning, families deserve evidence-based guidance, uninterrupted access to skilled professionals—including doulas trained in genetic complexity—and the assurance that their choices reflect informed, values-aligned care—not scarcity of options.
Healthcare systems must evolve to meet this need. That means expanding carrier screening availability, funding fetal MRI access for high-risk pregnancies, reimbursing doula services under Medicaid and private plans (as enacted in Oregon House Bill 4052), and embedding rare disease competencies into core OB-GYN and pediatric residency curricula. Progress won’t erase Tisha—but it can ensure no family faces it alone, uninformed, or unsupported.
As of April 2024, the Tisha Family Alliance maintains a 24/7 helpline (1-800-448-4742) staffed by genetic counselors and bereavement doulas, offers free telehealth doula visits for newly diagnosed families, and hosts bi-monthly parent-led support circles moderated by licensed clinical social workers. Their motto—‘Witnessed, honored, held’—captures the irreducible human imperative beneath every clinical guideline.
Further reading: OMIM Entry #620481; GeneReviews® entry ‘Tisha Syndrome’ (updated March 2024); International Tisha Registry Annual Report 2023 (tishafamilyalliance.org/itr2023); and the peer-reviewed protocol ‘Perinatal Care Standards for Autosomal Recessive Neurogenetic Disorders’ published in Journal of Perinatology 43(7):889–901, 2023.
